TipRanks
Chugai Pharmaceutical Co Ltd (MX:4519N)
:4519N
Mexico Market
4519N
Chugai Pharmaceutical Co
RESEARCH TOOLSreports

Chugai Pharmaceutical Co (4519N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4519N Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
6 Buy
5 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Chugai
Pharmaceutical Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4519N Stock 12 Month Forecast

Average Price Target

$982.23
▲(18.97% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Chugai Pharmaceutical Co in the last 3 months. The average price target is $982.23 with a high forecast of $1,522.25 and a low forecast of $698.18. The average price target represents a 18.97% change from the last price of $825.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"697":"$697","1110":"$1,110","1523":"$1,523","903.5":"$903.5","1316.5":"$1,316.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1522.251367,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.52K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":982.2319141818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$982.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":698.175439,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$698.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[697,903.5,1110,1316.5,1523],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,732.85,793.5731820769231,854.2963641538462,915.0195462307693,975.7427283076923,1036.4659103846154,1097.1890924615386,1157.9122745384616,1218.6354566153846,1279.3586386923077,1340.081820769231,1400.805002846154,1461.5281849230769,{"y":1522.251367,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,732.85,752.0332241678321,771.2164483356644,790.3996725034965,809.5828966713286,828.7661208391609,847.949345006993,867.1325691748252,886.3157933426573,905.4990175104895,924.6822416783217,943.8654658461538,963.0486900139861,{"y":982.2319141818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,732.85,730.1827260769231,727.5154521538461,724.8481782307692,722.1809043076923,719.5136303846153,716.8463564615384,714.1790825384616,711.5118086153847,708.8445346923077,706.1772607692308,703.5099868461539,700.8427129230769,{"y":698.175439,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":785.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.78,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.78,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":962.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":962.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":825.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":825.61,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":825.61,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":825.61,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":732.85,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,522Average Price Target$982.23Lowest Price Target$698.18
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Macquarie Analyst forecast on MX:4519N
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$1,144.55→$869.86
Buy
5.36%
Upside
Reiterated
09/29/26
Macquarie Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
Jefferies Analyst forecast on MX:4519N
Stephen Barker
Jefferies
Jefferies
$915.64→$698.18
Hold
-15.44%
Downside
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Healthequity (NASDAQ: HQY) and Chugai Pharmaceutical Co (Other OTC: CHGCF)
Daiwa Analyst forecast on MX:4519N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$1,018.65
Buy
23.38%
Upside
Reiterated
09/28/26
Daiwa Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
SBI Securities Analyst forecast on MX:4519N
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
$1,087.32
Buy
31.70%
Upside
Reiterated
09/09/26
SBI Securities Sticks to Their Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Nomura Analyst forecast on MX:4519N
Unknown Analyst
Nomura
Not Ranked
Nomura
$915.64→$869.86
Hold
5.36%
Upside
Reiterated
09/01/26
Nomura Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Mizuho Securities Analyst forecast on MX:4519N
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$944.25→$812.63
Hold
-1.57%
Downside
Reiterated
08/19/26
Mizuho Securities Sticks to Their Hold Rating for Chugai Pharmaceutical Co (CHGCF)
Bank of America Securities Analyst forecast on MX:4519N
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$1,007.2→$858.41
Hold
3.97%
Upside
Reiterated
08/14/26
Bank of America Securities Remains a Hold on Chugai Pharmaceutical Co (CHGCF)
UBS Analyst forecast on MX:4519N
Unknown Analyst
UBS
Not Ranked
UBS
$1,121.66→$824.08
Hold
-0.19%
Downside
Downgraded
08/06/26
UBS downgrades Chugai Pharmaceutical Co (CHGCF) to a Hold
Citi Analyst forecast on MX:4519N
Unknown Analyst
Citi
Not Ranked
Citi
$1,545.14→$1,522.25
Buy
84.38%
Upside
Reiterated
07/28/26
Citi Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
Morgan Stanley Analyst forecast on MX:4519N
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
$1,121.66
Buy
35.86%
Upside
Reiterated
07/27/26
Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Morgan Stanley
Bernstein Analyst forecast on MX:4519N
Miki Sogi
Bernstein
Bernstein
$1,121.66
Buy
35.86%
Upside
Reiterated
07/07/26
Bernstein Sticks to Its Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Goldman Sachs Analyst forecast on MX:4519N
Akinori Ueda
Goldman Sachs
Goldman Sachs
$1,024.37
Buy
24.07%
Upside
Upgraded
06/15/26
Goldman Sachs upgrades Chugai Pharmaceutical Co (CHGCF) to a Buy
J.P. Morgan Analyst forecast on MX:4519N
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$1,259
Buy
52.49%
Upside
Reiterated
05/27/26
J.P. Morgan Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
SMBC Nikko Analyst forecast on MX:4519N
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
$1,087.32→$1,224.67
Buy
48.33%
Upside
Reiterated
02/25/26
Chugai Pharmaceutical Co (CHGCF) Receives a Buy from SMBC Nikko
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Macquarie Analyst forecast on MX:4519N
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$1,144.55→$869.86
Buy
5.36%
Upside
Reiterated
09/29/26
Macquarie Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
Jefferies Analyst forecast on MX:4519N
Stephen Barker
Jefferies
Jefferies
$915.64→$698.18
Hold
-15.44%
Downside
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Healthequity (NASDAQ: HQY) and Chugai Pharmaceutical Co (Other OTC: CHGCF)
Daiwa Analyst forecast on MX:4519N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$1,018.65
Buy
23.38%
Upside
Reiterated
09/28/26
Daiwa Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
SBI Securities Analyst forecast on MX:4519N
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
$1,087.32
Buy
31.70%
Upside
Reiterated
09/09/26
SBI Securities Sticks to Their Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Nomura Analyst forecast on MX:4519N
Unknown Analyst
Nomura
Not Ranked
Nomura
$915.64→$869.86
Hold
5.36%
Upside
Reiterated
09/01/26
Nomura Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Mizuho Securities Analyst forecast on MX:4519N
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$944.25→$812.63
Hold
-1.57%
Downside
Reiterated
08/19/26
Mizuho Securities Sticks to Their Hold Rating for Chugai Pharmaceutical Co (CHGCF)
Bank of America Securities Analyst forecast on MX:4519N
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$1,007.2→$858.41
Hold
3.97%
Upside
Reiterated
08/14/26
Bank of America Securities Remains a Hold on Chugai Pharmaceutical Co (CHGCF)
UBS Analyst forecast on MX:4519N
Unknown Analyst
UBS
Not Ranked
UBS
$1,121.66→$824.08
Hold
-0.19%
Downside
Downgraded
08/06/26
UBS downgrades Chugai Pharmaceutical Co (CHGCF) to a Hold
Citi Analyst forecast on MX:4519N
Unknown Analyst
Citi
Not Ranked
Citi
$1,545.14→$1,522.25
Buy
84.38%
Upside
Reiterated
07/28/26
Citi Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
Morgan Stanley Analyst forecast on MX:4519N
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
$1,121.66
Buy
35.86%
Upside
Reiterated
07/27/26
Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Morgan Stanley
Bernstein Analyst forecast on MX:4519N
Miki Sogi
Bernstein
Bernstein
$1,121.66
Buy
35.86%
Upside
Reiterated
07/07/26
Bernstein Sticks to Its Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Goldman Sachs Analyst forecast on MX:4519N
Akinori Ueda
Goldman Sachs
Goldman Sachs
$1,024.37
Buy
24.07%
Upside
Upgraded
06/15/26
Goldman Sachs upgrades Chugai Pharmaceutical Co (CHGCF) to a Buy
J.P. Morgan Analyst forecast on MX:4519N
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$1,259
Buy
52.49%
Upside
Reiterated
05/27/26
J.P. Morgan Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
SMBC Nikko Analyst forecast on MX:4519N
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
$1,087.32→$1,224.67
Buy
48.33%
Upside
Reiterated
02/25/26
Chugai Pharmaceutical Co (CHGCF) Receives a Buy from SMBC Nikko
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
WSTWest Pharmaceutical Services
ZYMEZymeworks
SLDBSolid Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Chugai Pharmaceutical Co

3 Months
Seiji WakaoJ.P. Morgan
Success Rate
4/6 ratings generated profit
67%
Average Return
+9.65%
Copying Seiji Wakao's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.65% per trade.
1 Year
Tony RenMacquarie
Success Rate
3/5 ratings generated profit
60%
Average Return
-4.58%
Copying Tony Ren's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -4.58% per trade.
2 Years
Seiji WakaoJ.P. Morgan
Success Rate
1/6 ratings generated profit
17%
Average Return
-10.15%
Copying Seiji Wakao's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -10.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4519N Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
1
1
1
0
Buy
4
6
5
7
3
Hold
9
5
5
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
12
11
14
8
In the current month, 4519N has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 4519N average Analyst price target in the past 3 months is 982.23.
Each month's total comprises the sum of three months' worth of ratings.

4519N Financial Forecast

4519N Earnings Forecast

Next quarter’s earnings estimate for 4519N is $8.58 with a range of $8.37 to $8.73. The previous quarter’s EPS was $7.87. 4519N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4519N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4519N is $8.58 with a range of $8.37 to $8.73. The previous quarter’s EPS was $7.87. 4519N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4519N has Performed in-line its overall industry.

4519N Sales Forecast

Next quarter’s sales forecast for 4519N is $39.38B with a range of $37.53B to $40.54B. The previous quarter’s sales results were $39.10B. 4519N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4519N has Performed in-line its overall industry.
Next quarter’s sales forecast for 4519N is $39.38B with a range of $37.53B to $40.54B. The previous quarter’s sales results were $39.10B. 4519N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4519N has Performed in-line its overall industry.

4519N Stock Forecast FAQ

What is MX:4519N’s average 12-month price target, according to analysts?
Based on analyst ratings, Chugai Pharmaceutical Co Ltd’s 12-month average price target is 982.23.
    What is MX:4519N’s upside potential, based on the analysts’ average price target?
    Chugai Pharmaceutical Co Ltd has 18.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Chugai Pharmaceutical Co Ltd a Buy, Sell or Hold?
          Chugai Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Chugai Pharmaceutical Co Ltd’s share price target?
            The average share price target for Chugai Pharmaceutical Co Ltd is 982.23. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,522.25 ,and the lowest forecast is $698.18. The average share price target represents 18.97% Increase from the current price of $825.61.
              What do analysts say about Chugai Pharmaceutical Co Ltd?
              Chugai Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Chugai Pharmaceutical Co Ltd?
                To buy shares of MX:4519N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.